News
Resources
Blog
Sites
Stephanie Fischer Stephanie is former Senior Director of Communications at PhRMA, focusing on science advocacy and regulatory issues. As a rare disease patient and stroke survivor, she is very passionate about the need for public policy that encourages innovation and the development of safe and effective new therapies.
Recent Posts
New Report Highlights a Decade of Innovation in Rare Diseases
By Stephanie Fischer | March 5, 2015
Despite Scientific Challenges, Biopharmaceutical Researchers Making Progress against Rare Disease While any given rare disease affects fewer than 200,000 people in the U.S., rare diseases...
Read More
Empowering Patients to Be Active Participants in Clinical Trials
By Stephanie Fischer | October 2, 2014
One of the topics of discussion at the recent Rare Patient Advocacy Summit hosted by Global Genes was the role of patients in healthcare. A statement that clearly resonated with the audience, from...
Read More
Collaboration is What Will Help Drive New Successes for the Rare Disease Community
By Stephanie Fischer | March 26, 2014
While the number of patients with any individual rare disease is relatively small (less than 200,000 in the U.S., as defined by the Orphan Drug Act of 1983), they collectively affect 1 in 10 Americans
Read More
NORD on the Need for More Collaboration to Drive Progress for Rare Disease Patients
By Stephanie Fischer | February 17, 2014
Many biopharmaceutical companies are actively engaged in the research and development of therapies to treat rare disease, despite challenges such as much smaller patient populations than more common...
Read More
#RarePOV Conversation Generates Strong Enthusiasm for Rare Disease Day on February 28th
By Stephanie Fischer | February 12, 2014
In last week’s #RarePOV tweetchat, leading rare disease advocacy organizations and individual patient advocates came together to share resources and plans for the upcoming international Rare Disease...
Read More
Addressing Challenges in Rare Disease Drug Development - Together
By Stephanie Fischer | January 27, 2014
Dr. Richard Moscicki, Deputy Center Director for Science Operations at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), noted in his remarks at the FDA public...
Read More
Rare Disease Community Loses a Champion
By Stephanie Fischer | January 15, 2014
The rare disease community lost a champion last week when Sam Berns passed away at age 17 due to complications from progeria, an extremely rare genetic disease which causes accelerated aging. Last...
Read More
Know the Signs of Stroke and Act Quickly
By Stephanie Fischer | May 14, 2013
May 15, 2003 came to be known as the Very Bad Day. It started off like any other, and I remember thinking in the morning that work was quieter than expected. Several hours later, I was in the ICU...
Read More
Patent Settlements Benefit Consumers
By Stephanie Fischer | March 25, 2013
The Supreme Court heard arguments today in the case of Federal Trade Commission v. Actavis, Inc. which addresses whether innovator biopharmaceutical companies can continue to enter into certain kinds...
Read More
PDUFA: Still a weird word worth knowing
By Stephanie Fischer | January 24, 2013
As my predecessor noted, PDUFA is indeed a weird word worth knowing. The Prescription Drug User Fee Act (PDUFA), reauthorized last year as part of the Food and Drug Administration (FDA) Safety and...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
